Analytical Data
-
Gene name
GABRA1-GABRB2-GABRG2
- Application
-
Alternative Names
GABA(A) receptor subunit beta-2
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P47870
-
Expression Region
26-244aa
-
Molecular Weight
29.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GABRA1, GABRB2, and GABRG2 are subunits of the GABAA receptor, a pivotal ionotropic receptor in the central nervous system that mediates inhibitory neurotransmission through the binding of gamma-aminobutyric acid (GABA). The GABAA receptor is a major target for various pharmacological agents, including anxiolytics, anticonvulsants, and sedatives. Deficiencies or mutations in these subunits have been associated with several neurological disorders, such as epilepsy, sleep disorders, and other neuropsychiatric conditions. Research on the recombinant proteins of GABRA1, GABRB2, and GABRG2 is crucial for understanding the receptor’s structure-function relationships, which can provide insights into how alterations at the molecular level can lead to disease. Moreover, recombinant proteins allow for the exploration of the receptor's pharmacological properties and its interactions with various ligands. By generating and characterizing these recombinant subunits, scientists aim to elucidate their roles in receptor assembly, trafficking, and function; this knowledge is essential for developing targeted therapies that modulate GABAergic signaling and address conditions arising from its dysregulation.
